Lowenstein Sandler advised Sonnet BioTherapeutics, while Sullivan & Worcester advised Chardan Capital Markets on the offering.Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN), a clinical-stage company developing innovative…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
